Business Wire

David Hart Appointed New CEO of the Bermuda Business Development Agency (BDA)

7.9.2021 18:57:00 EEST | Business Wire | Press release

Share

The Bermuda Business Development Agency (BDA) announced today that Mr. David Hart has been appointed as the new Chief Executive Officer (CEO) of the BDA effective 1 October 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210907005694/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

David Hart, new BDA CEO (Photo: Business Wire)

Prior to joining the BDA, Mr. Hart served as Executive Vice President of the Florida Chamber of Commerce, one of the largest and most successful business advocacy organisations in the United States, where he was part of the leadership team responsible for consistently enhancing the environment to increase job growth, diversify the economy and attract additional capital investments. Through collaborations with public and private sector partners these efforts contributed to Florida creating one of every 11 jobs in the United States, attracting $1.19 million in capital every hour, and recently becoming ranked as the 15th largest economy in the world.

Mr. Hart said, “I am very excited and honoured to be joining the BDA team. The BDA’s mission of fostering sustainable, equitable prosperity for Bermuda, and encouraging jobs, investment, and innovation to come to the Island, has never been more important. I am thrilled to join a world class team and accelerate our efforts to bring investment and jobs to Bermuda. Bermuda’s track record of leadership on a global scale, access to world markets and talented pool of human capital are significant strengths as we seek to diversify Bermuda’s economy and support our trading partners worldwide.”

Stephen Weinstein, BDA Chair said, “On behalf of the Board of Directors, we welcome Mr. Hart to the BDA and the Bermuda community at this critical time. His leadership, communication skills, and deep experience in economic development and public policy, are perfect fits for our next stage of challenges and growth.”

“We thank Roland Andy Burrows for nearly three years of dedicated service as CEO,” Mr. Weinstein said. “Under his leadership, the BDA helped navigate Bermuda through one of its most trying economic periods and we wish him well in his future endeavours.”

Mr. Burrows will continue to support the agency as a senior consultant through year-end to support the leadership transition.

Mr. Burrows said, "The BDA plays a vital role in promoting Bermuda. I am proud of what the BDA has achieved since December 2018 and will continue to support its mission.”

Mr. Hart’s new appointment highlights the Board’s and the BDA’s continued commitment to international business development. With an aim to increase international investment through innovation, strategic partnerships and targeted marketing of Bermuda’s world class business platform, the BDA has also created a new Business Development Committee chaired by BDA board member George Thomas. Mrs. Susan Pateras, BDA Deputy Chair, has been appointed Interim CEO and will oversee operations until Mr. Hart commences service. Mr. Hart’s service in Bermuda is subject to Bermuda Immigration approval.

CONNECTING BUSINESS

The BDA encourages direct investment and helps companies start up, re-locate or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. Our goal? To make doing business in Bermuda smooth and beneficial.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Stuart Roberts, Director of Communications & PR
stuart@bda.bm
+1 441 707 0038

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye